[1] |
Guo H,Callaway JB,Ting JP.Inflammasomes: mechanism of action, role in disease, and therapeutics[J].Nat Med,2015,21(7):677-687.
|
[2] |
Park SH,Shin EC.Direct ex vivo functional analysis of HCV-specific t cells[J].Methods Mol Biol,2019,1911:349-361.
|
[3] |
Estevez J,Chen VL,Podlaha O,et al.Differential serum cytokine profiles in patients with chronic hepatitis b,c,and hepatocellular carcinoma[J].Sci Rep,2017,7(1):11867.
|
[4] |
Yang R,Gao N,Chang Q,et al.The role of IDO,IL-10, and TGF-beta in the HCV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma[J].J Med Virol,2019,91(2):265-271.
|
[5] |
中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2015更新版)[J].中华临床感染病杂志,2015,8(6):504-525.
|
[6] |
Pang X,Wang Z,Zhai N,et al.IL-10 plays a central regulatory role in the cytokines induced by hepatitis C virus core protein and polyinosinic acid:polycytodylic acid[J].Int Immunopharmacol,2016,38:284-290.
|
[7] |
Niesen E,Schmidt J,Flecken T,et al.Suppressive effect of interleukin 10 on priming of naive hepatitis C virus-specific CD8+ T cells[J].J Infect Dis,2015,211(5):821-826.
|
[8] |
Liu BS,Groothuismink ZM,Janssen HL,et al.Role for IL-10 in inducing functional impairment of monocytes upon TLR4 ligation in patients with chronic HCV infections[J].J Leukoc Biol,2011,89(6):981-988.
|
[9] |
Couper KN,Blount DG,Riley EM.IL-10: the master regulator of immunity to infection[J].J Immunol,2008,180(9):5771-5777.
|
[10] |
Flynn JK,Dore GJ,Hellard M,et al.Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users[J].J Viral Hepat,2011,18(8):549-561.
|
[11] |
Antoniades CG,Wendon J,Vergani D.Paralysed monocytes in acute on chronic liver disease[J].J Hepatol,2005,42(2):163-165.
|
[12] |
Fabregat I,Caballero-Díaz D.Transforming Growth Factor-β-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis[J].Frontiers in Oncology,2018,8:357.
|
[13] |
Verma V,Chakravarti A,Kar P.Cytokine levels of TGF-beta, IL-10, and sTNFalphaRII in type C chronic liver disease[J].Dig Dis Sci,2008,53(8):2233-2237.
|
[14] |
Fabregat I,Moreno-Caceres J,Sanchez A,et al.TGF-beta signalling and liver disease[J].FEBS J,2016,283(12):2219-2232.
|
[15] |
Sheng J,Chen W,Zhu HJ.The immune suppressive function of transforming growth factor-beta(TGF-beta)in human diseases[J].Growth Factors,2015,33(2):92-101.
|
[16] |
Martinez-Esparza M,Tristan-Manzano M,Ruiz-Alcaraz AJ,et al.Inflammatory status in human hepatic cirrhosis[J].World J Gastroenterol,2015,21(41):11522-11541.
|
[17] |
Segura-Cerda CA,Aceves-Sanchez MJ,Perez-Koldenkova V,et al.Macrophage infection with combinations of BCG mutants reduces induction of TNF-alpha, IL-6, IL-1beta and increases IL-4[J].Tuberculosis (Edinb),2019,115:42-48.
|
[18] |
Waqas S,Ampem G,Roszer T.Analysis of IL-4/STAT6 Signaling in Macrophages[J].Methods Mol Biol,2019,1966:211-224.
|
[19] |
Zhao J,Jiang L,Deng L,et al.Important roles of CD32 in promoting suppression of IL-4 induced immune responses by a novel anti-IL-4 Ralpha therapeutic antibody[J].MAbs,2019:11(5):837-847.
|
[20] |
Impellizzieri D,Ridder F,Raeber ME,et al.IL-4 receptor engagement in human neutrophils impairs their migration and extracellular trap formation[J].J Allergy Clin Immunol,2019,144(1):267-279.
|
[21] |
Boccardi V,Westman E,Pelini L,et al.Differential associations of IL-4 with hippocampal subfields in mild cognitive impairment and alzheimer's disease[J].Front Aging Neurosci,2019,10:439.
|
[22] |
Carneros D,Santamaria EM,Larequi E,et al.Cardiotrophin-1 is an anti-inflammatory cytokine and promotes IL-4-induced M2 macrophage polarization[J].FASEB J,2019,33(6):7578-7587.
|
[23] |
Hao G,Duan W,Sun J,et al.Effects of febuxostat on serum cytokines IL-1,IL-4,IL-6, IL-8, TNF-alpha and COX-2[J].Exp Ther Med,2019,17(1):812-816.
|
[24] |
Ha JW,You MJ,Park HS,et al.Differential effect of LPS and paclitaxel on microglial functional phenotypes and circulating cytokines: the possible role of CX3CR1 and IL-4/10 in blocking persistent inflammation[J].Arch Pharm Res,2019,42(4):359-368.
|